Elranatamab: How it works, how it's being used, and how it compares to other bispecifics.
Elranatamab is a new treatment option that we will explore with Dr. Alex Lesokhin. Come learn how it works; how it compares to other bispecifics; and who might benefit from this new treatment option.
Cynthia introduces the agenda of the event and featured speaker Dr. Alex Lesokhin
Dr. Alex Lesokhin talks about Elranatamab
Type your questions in the chat and we will answer them!
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Dr. Alexander Lesokhin
Alexander Lesokhin, MD, is a Hematologic Oncologist at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY, who specializes in myeloma and immunology. His research work involves developing innovative ways to use the immune system to treat cancer. He conducts clinical studies of medicines that enhance the immune response as well as laboratory studies aimed at understanding how cancers such as multiple myeloma are able to evade the immune response with a goal of developing new ways to treat myeloma patients. Dr. Lesohkin completed his fellowship at MSKCC and his residency at New York-Presbyterian Hospital/Columbia University Medical Center. He earned his medical degree at the Albert Einstein College of Medicine in New York.